Evidence map›Paper›PMID 35613600›Full record

ReviewInquiry : a journal of medical care organization, provision and financing

The Effects of the SARS-CoV-2 Virus on the Cardiovascular System and Coagulation State Leading to Cardiovascular Diseases: A Narrative Review.

Rafiq A Bhat, Syed Maqbool, Akanksha Rathi, Syed Manzoor Ali, Yoosuf Ali Ashraf Muhammad Hussenbocus, Xiao Wentao, Yongsheng Qu, You Zhang, Yuxiao Sun, Hai-Xia Fu and 7 more

Open access · goldAbstract readReview
In one paragraph

Review in Inquiry : a journal of medical care organization, provision and financing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Rafiq A BhatDepartment of Interventional Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou University, Zhengzhou, People's Republic of China; Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
Syed MaqboolDepartment of Cardiology, Government Superspeciality Hospital, Srinagar, India.
Akanksha RathiDepartment of Community Medicine, Vedanta Institute of Medical Sciences, Palghar, India.
Syed Manzoor AliDepartment of Cardiology, Super Speciality Division, Government Medical College, Srinagar, India.
Yoosuf Ali Ashraf Muhammad HussenbocusDepartment of Rheumatology and Immunology, 12461Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.ORCID 0000-0002-3650-269X
Xiao WentaoDepartment of Interventional Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou University, Zhengzhou, People's Republic of China; Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
Yongsheng QuDepartment of Interventional Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou University, Zhengzhou, People's Republic of China; Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
You ZhangDepartment of Interventional Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou University, Zhengzhou, People's Republic of China; Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
Yuxiao SunDepartment of Interventional Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou University, Zhengzhou, People's Republic of China; Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
Hai-Xia FuDepartment of Interventional Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou University, Zhengzhou, People's Republic of China; Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
Ling Yun WangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Atul DwivediDepartment of Clinical and Basic Sciences, Medical School of Hubei Polytechnic University, Hubei, China.
Javaid Akhter BhatState Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China.
Raja Saqib IqbalDepartment of Paediatrics, Batra Hospital and Medical Research Centre, New Delhi, India.
Md Monowarul IslamDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Abhishek TibrewalDepartment of Community Medicine, Institute of Biostatistics and Epidemiology, Gurgaon, India.
Chuanyu GaoDepartment of Interventional Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou University, Zhengzhou, People's Republic of China; Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CNBatra Hospital and Medical Research Centre · INGovernment Medical College · INHubei Polytechnic University · CNInstitute of Medical Sciences · INNanjing Agricultural University · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel coronavirus pandemic has led to morbidity and mortality throughout the world. Until now, it is a highly virulent contagion attacking the respiratory system in humans, especially people with chronic diseases and the elderly who are most vulnerable. A majority of afflicted are those suffering from cardiovascular and coronary diseases. In this review article, an attempt has been made to discuss and thoroughly review the mode of therapies that alleviate cardiac complications and complications due to hypercoagulation in patients infected with the SARS-CoV-2 virus. Presently a host of thrombolytic drugs are in use like Prourokinase, Retelapse, RhTNK-tPA and Urokinase. However, thrombolytic therapy, especially if given intravenously, is associated with a serious risk of intracranial haemorrhage, systemic haemorrhage, immunologic complications, hypotension and myocardial rupture. The effects of the SARS-CoV-2 virus upon the cardiovascular system and coagulation state of the body are being closely studied. In connection to the same, clinical prognosis and complications of thrombolytic therapy are being scrutinized. It is noteworthy to mention that myocardial oxygen supply/demand mismatch, direct myocardial cells injury and acute plaque rupture are the multiple mechanisms responsible for acute coronary syndrome and cardiac complications in Covid-19 infection. However, this review has limitations as data available in this context is limited, scattered and heterogenous that questions the reliability of the same. So, more multi-centric studies involving representative populations, carried out meticulously, could further assist in responding better to cardiac complications among Covid-19 patients.

Indexed as

Cardiovascular DiseasesCardiovascular SystemCOVID-19AgedHumansReproducibility of ResultsSARS-CoV-2cardiovascular diseasescardiovascular systemhypercoagulationSARS-CoV-2ST elevation myocardial infarctionthrombolytic therapy

Identifiers

PMID35613600
PMCPMC9149622
OpenAlexW4281996414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.